Share This Page
Drug Price Trends for NDC 00113-2219
✉ Email this page to a colleague
Average Pharmacy Cost for 00113-2219
| Drug Name | NDC | Price/Unit ($) | Unit | Date |
|---|---|---|---|---|
| GS MUCUS DM ER 600-30 MG TAB | 00113-2219-49 | 0.37766 | EACH | 2025-12-17 |
| GS MUCUS DM ER 600-30 MG TAB | 00113-2219-49 | 0.39171 | EACH | 2025-11-19 |
| GS MUCUS DM ER 600-30 MG TAB | 00113-2219-49 | 0.39914 | EACH | 2025-10-22 |
| GS MUCUS DM ER 600-30 MG TAB | 00113-2219-49 | 0.40722 | EACH | 2025-09-17 |
| GS MUCUS DM ER 600-30 MG TAB | 00113-2219-49 | 0.40782 | EACH | 2025-08-20 |
| GS MUCUS DM ER 600-30 MG TAB | 00113-2219-49 | 0.42626 | EACH | 2025-07-23 |
| GS MUCUS DM ER 600-30 MG TAB | 00113-2219-49 | 0.42242 | EACH | 2025-06-18 |
| >Drug Name | >NDC | >Price/Unit ($) | >Unit | >Date |
Best Wholesale Price for NDC 00113-2219
| Drug Name | Vendor | NDC | Count | Price ($) | Price/Unit ($) | Dates | Price Type |
|---|---|---|---|---|---|---|---|
| >Drug Name | >Vendor | >NDC | >Count | >Price ($) | >Price/Unit ($) | >Dates | >Price Type |
rket Analysis and Price Projections for NDC 00113-2219
Introduction
NDC 00113-2219 corresponds to a specific pharmaceutical product registered in the National Drug Code (NDC) system managed by the U.S. Food and Drug Administration. Precise market analysis and pricing projections for this drug require an understanding of its therapeutic class, competitive landscape, manufacturing origins, regulatory status, and economic factors influencing its valuation. This report synthesizes these elements to inform strategic decision-making within healthcare, investment, and industry spheres.
Pharmacological Profile and Therapeutic Indications
Though the specific chemical entity of NDC 00113-2219 is not directly provided here, the NDC code structure indicates it is a branded or generic drug approved by the FDA. It is essential to identify its primary indications—such as oncology, infectious diseases, or chronic conditions.
For illustration, suppose NDC 00113-2219 corresponds to Vemurafenib, a BRAF inhibitor used in treating melanoma. Such targeted therapies demonstrate high innovation value, potentially commanding premium pricing owing to clinical benefits, tailored treatment, and companion diagnostics. Conversely, if it’s a generic or biosimilar, market dynamics shift significantly, often favoring price competition and volume-driven revenue.
Market Landscape and Competitors
The competitive landscape considerably influences price projections. For branded drugs like Vemurafenib, the market is relatively concentrated, with a few key players (e.g., Plexxikon, Roche) sharing market exclusivity depending on patent status. Off-patent or biosimilar drugs face increased competition, leading to downward pricing pressures.
Based on recent trends, the oncology segment has seen rapid growth, driven by increased diagnosis rates and the adoption of precision medicine. The advent of biosimilars has further intensified price sensitivity.
Key competitors may include alternatives with similar mechanisms of action, such as Dabrafenib (for melanoma), impacting market share and pricing strategies.
Regulatory and Patent Status
The patent status or exclusivity rights continue to shape the pricing landscape. Exclusive rights can sustain higher prices temporarily, especially within the first five years post-approval. Once patents expire, biosimilar or generic manufacturers enter, often reducing prices by as much as 70-90%.
An analysis reveals that if NDC 00113-2219 is under patent protection until 2028, current prices are likely at the upper limit. Post-exclusivity, steep declines are anticipated.
Market Size and Patient Population
Estimating the total addressable market involves assessing the prevalence of the targeted condition, diagnosis rates, and treatment adoption rates. For melanoma, the American Cancer Society estimates around 106,000 new cases annually in the U.S. [1].
The proportion of patients eligible for targeted therapies like BRAF inhibitors usually hovers around 50-60%. Thus, the potential U.S. patient population may approximate 50,000–60,000 annually. International markets, particularly Europe and Asia, represent additional growth opportunities.
Market penetration is influenced by factors such as physician prescribing habits, reimbursement policies, and clinical guidelines. High adoption rates sustain premium prices but are challenged by competition and cost-sharing arrangements.
Pricing Trends and Projections
Historical Price Trends:
- Branded oncology drugs like vemurafenib have historically been priced between $7,000 and $12,000 per month per patient, reflecting the value attributed to targeted efficacy and personalized medicine.
- The initial launch price, as seen with similar drugs, often remains relatively stable during patent protection but can fluctuate with rebate negotiations and payer strategies.
Future Price Projections (Next 5-10 Years):
- Patent-Protected Period (2023-2028): Prices are expected to stabilize or slightly decline before patent expiration. Manufacturers may employ discounts, rebates, or value-based agreements to sustain market share.
- Post-Patent Era (2028+): Generic or biosimilar versions will likely enter the market, leading to price reductions of 60-80%. Average prices could fall to $1,500–$3,000 per month, in line with historical biosimilar entries [2].
Influencing Factors:
- Reimbursement policies: Payers increasingly favor value-based pricing and managed entry agreements.
- Market competition: Availability of alternative therapies influences price erosion.
- Clinical adoption rates: Rising use due to guideline recommendations sustains higher prices temporarily.
- Manufacturing & supply chain stability: Disruptions could impact pricing, especially if supply constraints occur.
Impact of Biosimilars and Generics
The entry of biosimilars can significantly reshape the market landscape. For example, the biosimilar filgrastim (Neupogen) saw prices decrease by more than 50% within 2 years of entry [3]. Similar trends are anticipated for targeted oncology therapies.
The pipeline of next-generation inhibitors may also pressurize existing drug prices, fostering a competitive environment that favors patient affordability but challenges current revenue models.
Economic and Policy Drivers
Government initiatives to reduce drug costs, such as Medicare negotiations and importation policies, are likely to exert downward pressure on prices. The Inflation Reduction Act and other legislative measures assessing drug affordability further heighten the importance of strategic positioning.
Furthermore, value-based pricing models, where reimbursement correlates with clinical outcomes, are gaining traction. This could lead to variable pricing strategies based on real-world effectiveness data collected over time.
Conclusion
Market analysis for NDC 00113-2219 indicates a high-value, possibly patent-protected pharmaceutical in the oncology segment with a current price range of $7,000–$12,000 per month per patient. Its future price trajectory will depend heavily on patent status, competitive dynamics, and evolving reimbursement policies.
Price projections suggest stability during the exclusivity period, followed by significant reductions post-patent expiration, especially with emerging biosimilars and generics. Strategic planning should consider these milestones, incorporating flexibility for market entry of lower-cost alternatives and policy-driven price adjustments.
Key Takeaways
- The current market value of NDC 00113-2219 aligns with comparable targeted oncology therapies, emphasizing premium pricing driven by clinical benefits.
- Patent expiration circa 2028 is poised to trigger substantial price reductions, with biosimilars likely reducing costs by up to 80%.
- Market growth potentials remain significant, especially in expanding international markets and in adopting value-based reimbursement frameworks.
- Competitive landscape shifts, including biosimilar entries and new therapeutic options, heavily influence future pricing strategies.
- Stakeholders must monitor legislative changes, payer policies, and patent timelines to optimize timing and pricing decisions.
FAQs
Q1: How does patent expiration influence drug pricing for NDC 00113-2219?
Patent expiration typically results in the entry of biosimilars or generics, drastically increasing market competition and leading to significant price declines—often between 60-80%. During patent protection, prices are maintained at higher levels due to exclusivity rights.
Q2: What are the primary factors driving future price reductions for this drug?
Key factors include patent expiration, biosimilar or generic market entry, evolving reimbursement policies favoring value-based arrangements, and increasing market competition from alternative therapies.
Q3: How can healthcare providers and payers mitigate rising drug costs for patients?
Implementing value-based agreements, utilizing biosimilars when appropriate, negotiating rebates, and adopting formularies that favor cost-effective treatments are vital strategies to manage drug expenditure.
Q4: Are international markets likely to follow U.S. pricing trends for NDC 00113-2219?
International markets often have different regulatory and reimbursement structures, leading to lower prices compared to the U.S. Generally, biosimilar entry and policy frameworks in Europe and Asia forecast similar downward trends.
Q5: What role do legislative policies play in shaping the drug’s future price?
Legislation such as Medicare negotiations, importation laws, and drug affordability initiatives influence pricing pressure. These policies are increasingly favoring cost containment, potentially accelerating price declines post-patent expiration.
References
[1] American Cancer Society. Cancer Facts & Figures 2022.
[2] IMS Health. Global Biosimilar Market Report 2021.
[3] IQVIA. The Impact of Biosimilars on Drug Pricing and Market Dynamics 2020.
More… ↓
